Dark Forest Capital Management LP Invests $616,000 in Liquidia Co. (NASDAQ:LQDA)

Dark Forest Capital Management LP bought a new stake in Liquidia Co. (NASDAQ:LQDA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 52,363 shares of the company's stock, valued at approximately $616,000. Dark Forest Capital Management LP owned about 0.06% of Liquidia at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of LQDA. LM Advisors LLC bought a new stake in shares of Liquidia in the 4th quarter valued at about $25,948,000. Invesco Ltd. increased its stake in Liquidia by 2,675.0% in the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock valued at $8,234,000 after purchasing an additional 674,940 shares in the last quarter. Mirabella Financial Services LLP acquired a new stake in Liquidia in the fourth quarter worth $5,880,000. Eversept Partners LP grew its holdings in shares of Liquidia by 314.1% in the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company's stock valued at $6,719,000 after buying an additional 433,356 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Liquidia in the 4th quarter valued at $2,681,000. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Stock Performance

LQDA traded up $0.05 on Thursday, hitting $14.02. 201,464 shares of the company were exchanged, compared to its average volume of 971,943. The stock's fifty day moving average is $14.25 and its 200-day moving average is $12.95. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.81. The company has a market cap of $1.20 billion, a PE ratio of -8.61 and a beta of 0.23.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, equities research analysts expect that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on LQDA shares. Needham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research report on Thursday, March 20th. Finally, Scotiabank reissued an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $26.63.

Insider Activity

In other news, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the transaction, the insider now directly owns 263,152 shares in the company, valued at approximately $3,597,287.84. The trade was a 0.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Roger Jeffs sold 14,130 shares of the firm's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the sale, the chief executive officer now directly owns 1,006,420 shares of the company's stock, valued at $13,657,119.40. This represents a 1.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock valued at $450,233 in the last quarter. Company insiders own 30.10% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).